95 related articles for article (PubMed ID: 12479856)
21. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity.
Fazioli F; Resnati M; Sidenius N; Higashimoto Y; Appella E; Blasi F
EMBO J; 1997 Dec; 16(24):7279-86. PubMed ID: 9405357
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation.
Zada AA; Singh SM; Reddy VA; Elsässer A; Meisel A; Haferlach T; Tenen DG; Hiddemann W; Behre G
Oncogene; 2003 Apr; 22(15):2296-308. PubMed ID: 12700665
[TBL] [Abstract][Full Text] [Related]
23. Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia.
Atfy M; Eissa M; Salah HE; El Shabrawy DA
Med Oncol; 2012 Sep; 29(3):2063-9. PubMed ID: 21638078
[TBL] [Abstract][Full Text] [Related]
24. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
[TBL] [Abstract][Full Text] [Related]
25. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells.
Jardí M; Inglés-Esteve J; Burgal M; Azqueta C; Velasco F; López-Pedrera C; Miles LA; Félez J
Thromb Haemost; 1996 Dec; 76(6):1009-19. PubMed ID: 8972026
[TBL] [Abstract][Full Text] [Related]
26. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells.
Mizukami IF; Todd RF
J Leukoc Biol; 1998 Aug; 64(2):203-13. PubMed ID: 9715260
[TBL] [Abstract][Full Text] [Related]
27. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts.
Tazzari PL; Cappellini A; Ricci F; Evangelisti C; Papa V; Grafone T; Martinelli G; Conte R; Cocco L; McCubrey JA; Martelli AM
Leukemia; 2007 Mar; 21(3):427-38. PubMed ID: 17215852
[TBL] [Abstract][Full Text] [Related]
28. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
Riccioni R; Pasquini L; Mariani G; Saulle E; Rossini A; Diverio D; Pelosi E; Vitale A; Chierichini A; Cedrone M; Foà R; Lo Coco F; Peschle C; Testa U
Haematologica; 2005 May; 90(5):612-24. PubMed ID: 15921376
[TBL] [Abstract][Full Text] [Related]
29. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
30. Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G.
Beaufort N; Leduc D; Rousselle JC; Magdolen V; Luther T; Namane A; Chignard M; Pidard D
J Immunol; 2004 Jan; 172(1):540-9. PubMed ID: 14688365
[TBL] [Abstract][Full Text] [Related]
31. Function of the urokinase receptor (CD87) in neutrophil chemotaxis.
Gyetko MR; Sitrin RG; Fuller JA; Todd RF; Petty H; Standiford TJ
J Leukoc Biol; 1995 Nov; 58(5):533-8. PubMed ID: 7595054
[TBL] [Abstract][Full Text] [Related]
32. Differential sensitivity of human myeloma cell lines and normal bone marrow colony forming cells to a recombinant diphtheria toxin-interleukin 6 fusion protein.
Chadwick DE; Jean LF; Jamal N; Messner HA; Murphy JR; Minden MD
Br J Haematol; 1993 Sep; 85(1):25-36. PubMed ID: 8251407
[TBL] [Abstract][Full Text] [Related]
33. uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
Guthaus E; Bürgle M; Schmiedeberg N; Hocke S; Eickler A; Kramer MD; Sweep CG; Magdolen V; Kessler H; Schmitt M
Biol Chem; 2002 Jan; 383(1):207-16. PubMed ID: 11930939
[TBL] [Abstract][Full Text] [Related]
34. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
Luther T; Magdolen V; Albrecht S; Kasper M; Riemer C; Kessler H; Graeff H; Müller M; Schmitt M
Am J Pathol; 1997 Apr; 150(4):1231-44. PubMed ID: 9094980
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of Mac-1(CD11b/CD18) and urokinase receptor (CD87).
Wong WS; Simon DI; Rosoff PM; Rao NK; Chapman HA
Immunology; 1996 May; 88(1):90-7. PubMed ID: 8707356
[TBL] [Abstract][Full Text] [Related]
36. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors.
Plasilova M; Zivny J; Jelinek J; Neuwirtova R; Cermak J; Necas E; Andera L; Stopka T
Leukemia; 2002 Jan; 16(1):67-73. PubMed ID: 11840265
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
[TBL] [Abstract][Full Text] [Related]
38. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
[TBL] [Abstract][Full Text] [Related]
39. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
40. Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias.
Perentesis JP; Bendel AE; Shao Y; Warman B; Davies SM; Yang CH; Chandan-Langlie M; Waddick KG; Uckun FM
Leuk Lymphoma; 1997 Apr; 25(3-4):247-56. PubMed ID: 9168435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
